Prosensa Holding N.V. (NASDAQ:RNA) was a big mover last session, as its shares rose nearly 12% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This continues the trend for the company since May 16, as the stock is now up over 63%. Prosensa Holding NV (NASDAQ:RNA) net profit margin is -27.60% and weekly performance is 66.62 %. On last trading day company shares ended up $11.03. Prosensa Holding NV (NASDAQ:RNA) distance from 50-day simple moving average (SMA50) is 75.19%.
On May 29, PTC Therapeutics Inc. (NASDAQ:PTCT) got a positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding its experimental Duchenne muscular dystrophy (DMD) treatment, Translarna. What makes this news significant is that earlier this year, the CHMP had issued a negative opinion for this very same treatment. PTC Therapeutics, Inc. (NASDAQ:PTCT) shares advanced 1.98% in last trading session and ended the day on $23.71. Its return on assets is -27.20%. PTC Therapeutics, Inc. (NASDAQ:PTCT) quarterly performance is -24.39%.
On May 29, Dyax Corp. (NASDAQ:DYAX) announced that executive management will participate in the Jefferies Global Healthcare Conference being held June 2-5, 2014 in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Monday, June 2 at 10:30 AM (ET). Mr. Christensen will provide a corporate update on the Company’s key value drivers – the KALBITOR® (ecallantide) business, DX-2930 and the LFRP. Dyax Corp. (NASDAQ:DYAX) shares moved down -2.94% in last trading session and was closed at $8.25, while trading in range of $8.22 – $8.54. Dyax Corp. (NASDAQ:DYAX) year to date (YTD) performance is 9.42%.
On May 28, 2014 Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced that Pratik Shah, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 8:30 a.m. EDT in New York City. Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) ended the last trading day at $21.15. Company weekly volatility is calculated as 7.91%. Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) showed a positive weekly performance of 24.12%.
On May 29, Orexigen Therapeutics, Inc. (NASDAQ:OREX) was a big mover last session with its shares rising over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $5.29 to $5.90. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is 19.19%. On last trading day company shares ended up $6.46. Analysts mean target price for the company is $11.86. Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average (SMA50) is 10.53%.